EXEL
vs
C
CANF
EXEL
Over the past 12 months, EXEL has significantly outperformed CANF, delivering a return of +20% compared to the CANF's 88% drop.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
EXEL
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
Exelixis Inc
NASDAQ:EXEL
|
45.065
USD
|
|||||
|
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
708.9
ILS
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
EXEL, CANF
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
Exelixis Inc
Revenue
|
|||||||||||
|
C
|
Can Fite Biopharma Ltd
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
EXEL, CANF
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
Exelixis Inc
NASDAQ:EXEL
|
|||||||||
|
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
|||||||||
Compare company's free cash flow with its competitors.
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Exelixis Inc | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Net Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Exelixis Inc | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
EXEL, CANF
Performance By Year
EXEL, CANF
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| AU |
|
CSL Ltd
ASX:CSL
|